

NEW ZEALAND DATA SHEET

1 PRODUCT NAME

Flucloxacillin Eugia Powder for Injection 500 mg

Flucloxacillin Eugia Powder for Injection 1 g

2 QUALITATIVE AND QUANTITATIVE COMPOSITION

The flucloxacillin is present as flucloxacillin sodium monohydrate in Flucloxacillin Eugia.

Each 0.544g (544.00 mg) of flucloxacillin sodium monohydrate equivalent to approximately 500 mg of anhydrous flucloxacillin.

Each 1.088 g (1088 mg) of flucloxacillin sodium monohydrate equivalent to approximately 1 g (1000 mg) of anhydrous flucloxacillin.

Flucloxacillin Eugia 500 mg powder for injection/infusion contains 500 mg flucloxacillin.

Flucloxacillin Eugia 1 g powder for injection/infusion contains 1 g flucloxacillin.

Excipient(s) with known effect

Flucloxacillin Eugia contains only flucloxacillin sodium monohydrate, with no additional ingredients.

Each one gram of flucloxacillin sodium monohydrate contains approximately 2.2 mmol of sodium.

3 PHARMACEUTICAL FORM

Flucloxacillin Eugia Powder for Injection vials: Glass vials containing a white to almost white powder for reconstitution.

4 CLINICAL PARTICULARS

4.1 Therapeutic Indications

Flucloxacillin Eugia is indicated in adults and children for the following:

- The treatment of skin and soft tissue infections caused by susceptible organisms and infections due to penicillinase producing staphylococci and for mixed streptococcal and staphylococcal infections where the staphylococci are resistant to penicillin. For example, infections of the joints, respiratory tract and urinary tract, otitis media, endocarditis, septicaemia, and meningitis.
- Prophylaxis of staphylococcal infections during major surgical procedures, particularly in cardiothoracic or orthopaedic surgery.

Consideration should be given to official guidance on the appropriate use of antibacterial agents.

4.2 Dose and method of administration

The dosage depends on the severity and nature of the infection.

The usual routes of administration are by intramuscular injection, slow intravenous injection and intravenous infusion. Flucloxacillin may also be administered by intra-articular or intrapleural injection.

Dose

Adults

By intramuscular injection: Usual dosage 250 mg every 6 hours.

By intravenous injection or infusion: Usual dosage 250 mg to 1 g every 6 hours.

By intrapleural injection: Usual dosage 250 mg once daily.

By Intra-articular injection: Usual dosage 250 mg to 500 mg once daily

Special populations

Paediatric population

Children up to 2 years of age: One quarter of the adult dose.

Children 2 years to 10 years: Half the adult dose.

Elderly population/Renal impairment

Dosage reduction is not usually required but is required in severe renal failure, creatinine clearance less than 10ml/min. In those instances, a reduction in dose or extension of dose is required.

Hepatic impairment

Adjustment of dosage may not be necessary as flucloxacillin is not metabolised in the liver to any appreciable extent. However, during prolonged treatment it is advisable to check periodically for hepatic dysfunction (see **Section 4.4 Special Warnings and Precautions for Use**).

Method of Administration

For instructions on reconstitution of the medicinal product before administration, see section 6.6.

Flucloxacillin Eugia may be administered either by slow intravenous injection over a period of 3 to 4 minutes directly into a vein or injected, suitably diluted, into the drip tube.

4.3 Contraindications

Flucloxacillin Eugia is contraindicated in patients who have had previous experience of a major allergy or anaphylaxis to a cephalosporin or penicillin.

Flucloxacillin Eugia is contraindicated in patients with a previous history of flucloxacillin-associated jaundice/hepatic dysfunction.

Flucloxacillin Eugia is contraindicated in patients with hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

Use in the eye.

4.4 Special warnings and precautions for use

Hepatic Toxicity

Flucloxacillin can cause severe hepatitis and cholestatic jaundice, which may be protracted. This reaction is more frequent in older patients and those who take the drug for prolonged periods (see Section 4.8 Undesirable Effects).

Anaphylaxis

Flucloxacillin Eugia should be given with caution to patients who have experienced symptoms of allergy associated with a cephalosporin or penicillin. Serious, and occasionally fatal, hypersensitivity (anaphylactoid) reactions have been reported in patients receiving beta-lactam antibiotics (e.g. penicillins). Anaphylaxis is more frequent following parenteral therapy.

Before commencing therapy with any penicillin, careful enquiry should be made concerning previous hypersensitivity reactions to penicillins, cephalosporins or other allergens. If an allergic reaction occurs; appropriate therapy should be instituted and Flucloxacillin Eugia therapy discontinued.

Serious anaphylactoid reactions require emergency treatment with adrenaline, oxygen, and intravenous steroids. Airway management including intubation, should also be administered as indicated.

As with any potent medicine, periodic assessment of renal, hepatic and haematopoietic function should be made during prolonged therapy. The possibility of superinfections with mycotic or bacterial pathogens should be kept in mind during therapy. If superinfections occur (usually involving *Aerobacter*, *Pseudomonas* or *Candida*), the medicine should be discontinued and/or appropriate therapy instituted.

Severe cutaneous adverse reactions

Severe cutaneous adverse reactions (SCAR), such as Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), drug reaction with eosinophilia and systemic symptoms (DRESS), and acute generalised exanthematous pustulosis (AGEP) have been reported in patients taking beta-lactam antibiotics. When SCAR is suspected, Flucloxacillin Eugia should be discontinued immediately and an alternative treatment should be considered.

The occurrence at the treatment initiation of a feverish generalised erythema associated with pustula may be a symptom of acute generalised exanthematous pustulosis (AGEP). In case of AGEP diagnosis, flucloxacillin should be discontinued and any subsequent administration of flucloxacillin contraindicated (See Section 4.8).

Use in hepatic impairment

Flucloxacillin Eugia should be used with caution in patients with evidence of hepatic dysfunction even though the latter is not a recognised predisposing factor to hepatic reactions to the drug.

Prolonged use of flucloxacillin may occasionally result in an overgrowth of non-susceptible organisms or yeast and patients should be observed carefully for superinfections.

Hepatitis, predominantly of a cholestatic type has been reported (see **Section 4.8 Undesirable Effects**) to be associated with Flucloxacillin Eugia therapy. Reports have been more frequent with increasing age (particularly over 55 years of age) or following prolonged treatment (more than 14 days). Jaundice may first appear several weeks after therapy: in some cases the course of the reactions has been protracted and lasted for several months. Resolution has occurred with time in most cases. In rare cases, patients have died of hepatitis associated with flucloxacillin nearly always in patients with serious underlying disease or receiving concomitant medication.

Use in renal impairment

The dose or dose interval may need modification in patients with renal failure as the half life in patients with renal failure is increased. As renal function is not fully developed in the neonate the risk/benefit ratio should be considered before administration to such patients.

Caution should be exercised in the treatment of patients with an allergic diathesis.

Very high doses of flucloxacillin can cause hypokalaemia and sometimes hypernatraemia. In patients undergoing high-dose treatment for more than 5 days, electrolyte balance, blood counts, and renal function should be monitored. Additionally, use of a potassium-sparing diuretic may be helpful.

Paediatric Use

Animal studies show that high doses of flucloxacillin reduce albumin-bound bilirubin to 50 to 70% of the base line concentration. Special caution is essential in neonates and premature infants because of the risk of hyperbilirubinemia. Flucloxacillin Eugia could potentially result in the reduction of albumin-bound bilirubin.

Pseudomembranous Colitis

Antibiotic associated pseudomembranous colitis has been reported with many antibiotics including flucloxacillin. A toxin produced by *Clostridium difficile* appears to be the primary cause. The severity of the colitis may range from mild to life threatening. It is important to consider this diagnosis in patients who develop diarrhoea or colitis in association with antibiotic use (this may occur up to several weeks after cessation of antibiotic therapy). Mild cases usually respond to drug discontinuation alone. However in moderate to severe cases, appropriate therapy with a suitable oral antibacterial agent effective against *Clostridium difficile* should be considered. Fluids, electrolytes and protein replacement should be provided when indicated. Drugs which delay peristalsis, e.g. opiates and diphenoxylate with atropine (Lomotil) may prolong and/or worsen the condition and should not be used. Diarrhoea may also occur after the cessation of therapy.

Caution should be exercised in the treatment of patients with an allergic diathesis.

High anion gap metabolic acidosis

Caution is advised when flucloxacillin is administered concomitantly with paracetamol due to the increased risk of high anion gap metabolic acidosis (HAGMA). Patients at high risk for HAGMA are in particular those with severe renal impairment, sepsis or malnutrition especially if the maximum daily doses of paracetamol are used.

After co-administration of flucloxacillin and paracetamol, a close monitoring is recommended in order to detect the appearance of acid-base disorders, namely HAGMA, including the search of urinary 5-oxoproline.

If flucloxacillin is continued after cessation of paracetamol, it is advisable to ensure that there are no signals of HAGMA, as there is a possibility of flucloxacillin maintaining the clinical picture of HAGMA (see section 4.5 Interactions with other medicines)

Use in the elderly

See Hepatitis

Effects on laboratory tests

No data available.

4.5 Interaction with other medicines and other forms of interaction

Aminoglycosides

It is recommended that flucloxacillin sodium for injection and aminoglycosides are not mixed together in the same solution for injection, due to possible precipitation and the gradual inactivation of the aminoglycosides under these circumstances (See section 6.2 Incompatibilities).

Blood products and proteinases

Flucloxacillin sodium for injections should not be mixed with blood products or other proteinase fluids (e.g. Protein hydrolysates).

Oestrogen Containing Oral Contraceptives

The efficacy of oral contraceptives may be impaired under concomitant administration of Flucloxacillin Eugia, which may result in unwanted pregnancy. Women taking oral contraceptives should be aware of this and should be informed about alternative methods of contraception.

Methotrexate

Penicillins reduce the excretion of methotrexate thereby increasing the risk of methotrexate toxicity.

Interference with diagnostic tests

Penicillins may interfere with:

- Urinary glucose test
- Commb's tests
- Tests for urinary or serum proteins
- Test which use bacteria e.g. Guthrie test.

Probenecid

Probenecid decreases the renal tubular secretion of penicillins when used concurrently, resulting in increased and more prolonged flucloxacillin serum concentrations and prolonged elimination half-life.

Bacteriostatic Antibiotics

Since bacteriostatic agents such as Chloramphenicol, Erythromycin, Sulfonamides or Tetracyclines may interfere with the bactericidal effect of penicillins in the treatment of meningitis or other situations where a rapid bactericidal effect is necessary, it is best to avoid concurrent therapy.

Paracetamol

Caution should be taken when flucloxacillin is used concomitantly with paracetamol as concurrent intake has been associated with high anion gap metabolic acidosis, especially in patients with risk factors. (See Section 4.4 Special Warnings and Precautions for Use).

Posaconazole and voriconazole

Flucloxacillin (a CYP450 inducer) has been reported to significantly decrease plasma posaconazole and voriconazole concentrations. If concomitant administration of flucloxacillin with either posaconazole or voriconazole cannot be avoided, monitor for potential loss of posaconazole or voriconazole effectiveness (e.g. by therapeutic drug monitoring); increasing the dose of posaconazole or voriconazole may be needed.

4.6 Fertility, pregnancy and lactation

Pregnancy

Australian Pregnancy Category: B1

Category B1: Drugs which have been taken by only a limited number of pregnant women and women of childbearing age, without an increase in the frequency of malformation or other direct or indirect harmful effects on the human foetus having been observed. Studies in animals have not shown evidence of an increased occurrence of foetal damage.

The safety of Flucloxacillin Eugi in the first trimester of pregnancy has not yet been established. Use in the second and third trimester of pregnancy has shown no significant risk to the neonate.

Studies in animals have not shown evidence of foetal damage. Pregnant women should be treated only if the expected benefit outweighs the possible risks to the pregnant woman and foetus.

Breast-feeding

Flucloxacillin is excreted in breast milk in trace amounts. An alternative feeding method is recommended to avoid any possible sensitisation of the newborn.

Fertility

There are no data available on fertility.

4.7 Effects on ability to drive and use machines

During treatment with Flucloxacillin Eugia Injection, undesirable effects may occur (e.g. allergic reactions, dizziness and convulsions) which may influence the ability to drive and use machines. Patients should be cautious when driving or operating machinery.

4.8 Undesirable effects

As with other penicillins, it may be expected that untoward reactions will be essentially limited to sensitivity phenomena.

They are more likely to occur in individuals who have previously demonstrated hypersensitivity to penicillins. Anaphylactic shock is most likely to occur with injected penicillins.

The following adverse reactions have been reported as associated with the use of flucloxacillin.

Blood and lymphatic disorders: Haemolytic anaemia has been reported during therapy with flucloxacillin. Reactions such as anaemia, thrombocytopenia, thrombocytopenic purpura, eosinophilia, leucopenia and agranulocytosis have been reported during therapy with other penicillins. These reactions are usually reversible on discontinuation of therapy and are believed to be hypersensitivity phenomena.

Immune system disorders: Erythematous maculopapular rashes, urticaria, purpura, eosinophilia, angioneurotic oedema, erythema nodosum, and cutaneous vasculitis. Anaphylaxis and erythema multiforme have been reported rarely. Certain reactions (fever, arthralgia and myalgia) sometimes develop more than 48 hours after the start of treatment. Whenever such reactions occur, the administration of Flucloxacillin Eugia should be discontinued. (Note: urticaria, other skin rashes and serum sickness-like reactions may be controlled with antihistamines and, if necessary, systemic corticosteroids).

Gastrointestinal disorders: Nausea, vomiting, diarrhoea, dyspepsia, constipation, abdominal pain, heart burn and loss of appetite. As with other antibiotics, pseudomembranous colitis has been reported rarely (see **Section 4.4 Special Warnings and Precautions for Use**).

Hepatobiliary disorders: A moderate rise in SGOT and cholestasis have been reported. Hepatitis and cholestatic jaundice (sometimes severe) with a frequency of about 1 in 15,000 exposures have been reported (see **Section 4.4 Special Warnings and Precautions for Use**).

These reactions are related neither to the dose nor to the route of administration. The onset of these effects may be delayed for up to two months post treatment. Hepatic events may be severe and in very rare circumstances (patients over 50 years of age with serious underlying disease) a fatal outcome had been reported.

Skin and subcutaneous tissue disorders: Erythematous maculopapular rashes, urticaria, erythema multiforme, cutaneous vasculitis. Whenever such reactions occur, Flucloxacillin Eugia should be discontinued.

Severe cutaneous adverse reactions, including Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), drug reaction with eosinophilia and systemic symptoms (DRESS), and acute generalised exanthematous pustulosis (AGEP), a red, scaly rash with bumps under the skin and blisters, have been reported in patients taking beta-lactam antibiotics.

Musculoskeletal and connective tissue disorders: Arthralgia and myalgia sometimes develop more than 48 hours after the start of treatment.

Renal and urinary disorders: Isolated cases of nephritis, interstitial nephritis. This is reversible when treatment is discontinued. Frequency of micturition and haematuria.

General disorders and administration site conditions: Fever sometimes develops more than 48 hours after the start of the treatment. Pain may be experienced at the site of intramuscular injection and phlebitis at the site of intravenous injection.

Metabolism and nutrition disorders: Post marketing experience: very rare cases of high anion gap metabolic acidosis, when flucloxacillin is used concomitantly with paracetamol, generally in the presence of risk factors (See Section 4.4).

Nervous system disorders: Adverse effects have been reported rarely. They include dizziness and convulsions. Convulsions may occur in patients with impaired renal function or in those receiving high doses. As the blood brain barrier becomes more permeable in meningitis, toxic symptoms may be precipitated by lower levels of flucloxacillin in patients with meningitis.

Respiratory, thoracic and mediastinal disorders: Bronchospasm.

Other: Malaise, bad taste, sore throat, sore tongue, pruritus vulvae, arthralgia, dizziness, depression and headache. Vaginal or oral moniliasis may occur following the use of antibiotics.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicine is important. It allows continued monitoring of the benefit/risk balance of the medicine. Healthcare professionals are asked to report any suspected reactions <https://pophealth.my.site.com/carmreportnz/s/>.

4.9 Overdose

Symptoms

With high parenteral doses of penicillins, neurotoxicity (e.g. convulsions, encephalopathy), blood disorders (e.g. neutropenia, haemolytic anaemia, prolongation of bleeding time, defective platelet function) or electrolyte disturbances may occur. As the blood brain barrier becomes more permeable in meningitis, toxic symptoms may be precipitated by lower levels of flucloxacillin in patients with meningitis.

Treatment

Treatment is symptomatic. Flucloxacillin Eugia is not removed from the circulation by haemodialysis.

For advice on the management of overdose please contact the National Poisons Centre on 0800 POISON (0800 764766).

5 PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

Pharmacotherapeutic group: BETA-LACTAM ANTIBACTERIALS, PENICILLINS- Beta-lactamase resistant penicillins, ATC code: J01CF05

Mechanism of action

Flucloxacillin is semi-synthetic penicillin with a narrow spectrum of bactericidal activity directed primarily against gram positive bacteria. Its mechanism of action is similar to that of benzyl penicillin in that it inhibits formation of the cell wall in susceptible species. Flucloxacillin Eugia is resistant to hydrolysis by acid and penicillinase.

5.2 Pharmacokinetic properties

Absorption

Flucloxacillin Eugia is well absorbed after an intramuscular administration. Peak serum concentrations after intramuscular administration of 250 mg-1 g may range from 5-15 mcg/mL after 30 minutes. Therapeutic concentrations persist for about 4 hours.

Distribution

Once absorbed, about 95% of Flucloxacillin Eugia in the circulation is bound to plasma protein. Flucloxacillin Eugia crosses the placental barrier and is excreted in breast milk, see section 4.6.

Biotransformation

Flucloxacillin Eugia is metabolised to a limited extent.

Elimination

The unchanged drug and metabolites are excreted by the kidneys by both tubular secretion and glomerular filtration. Approximately 90% of an intramuscular dose is excreted in the urine within 6 hours. The elimination half-life is short and variable having been measured in different studies between 0.5 – 1.5 h. The half-life is extended in neonates.

Special populations

Renal impairment

Elimination of Flucloxacillin Eugia is decreased in renal failure (see section 4.4).

5.3 Preclinical safety data

There are no pre-clinical data of relevance to the prescriber which are additional to those included in other sections.

6 PHARMACEUTICAL PARTICULARS

6.1 List of excipients

None.

6.2 Incompatibilities

Flucloxacillin sodium for injection is incompatible with aminoglycosides, amiodarone, atropine, buprenorphine, calcium gluconate, chlorpromazine, ciprofloxacin, diazepam, dobutamine, erythromycin lactobionate, metoclopramide, morphine sulphate, pefloxacin, pethidine, prochlorperazine edisylate and verapamil.

This medicinal product must not be mixed with other medicinal products except those mentioned in section 6.6.

Flucloxacillin Eugia should not be mixed with blood products, other proteinaceous fluids such as protein hydrolysates or with intravenous lipid emulsions.

Flucloxacillin Eugia may be used in combination with other antibiotics, particularly ampicillin, to produce a wider spectrum of activity. However, if prescribed concomitantly with an aminoglycoside, the antibiotics should not be mixed in the syringe, intravenous fluid container or giving set because of loss of activity of the aminoglycoside under these conditions.

6.3 Shelf life

Un-reconstituted dry powder Injection vials 36 months.

Reconstituted Flucloxacillin injection in water or other compatible infusion fluid (see section 6.6) is stable for at least 24 hours when stored at 5°C or for a period not exceeding 1 hour at room temperature. However, microbiological point of view must be considered, and the injection should be prepared immediately before use and any unused solution discarded.

6.4 Special precautions for storage

Store below 25°C.

6.5 Nature and contents of container

500 mg Powder Injection is packed in Type-I moulded clear, glass vials stoppered with chlorobutyl rubber stoppers and sealed with aluminium seal having polypropylene disc.

1000 mg Powder for Injection is packed in Type-I moulded clear glass vials stoppered with chlorobutyl rubber stoppers and sealed with aluminium seal having polypropylene disc.

Pack size:

1, 5 and 10 vials

Product is for single use in one patient only. Discard any residue.

Not all strengths or pack sizes may be marketed.

6.6 Special precautions for disposal and other handling

All prepared solutions should be checked for absence of particulate matter before use.

Since the dry powder in a vial displaces a set volume once it is in solution, this must be allowed for by calculating the volume of diluent to be added to ensure the correct dose is given.

500 mg of stated activity displaces 0.4 mL of diluent.

1 g of stated activity displaces 0.8 mL of diluent.

Preparation

Intravenous injection

Reconstitute 500 mg in 10 ml of water for injection

Reconstitute 1 g in 15 ml to 20 ml of water for injection

Intravenous infusion

Compatible infusion fluid: Flucloxacillin injection is compatible with the following infusion fluids for a period not exceeding 1 hour at room temperature: Dextrose 5%, Dextrose/Saline, 0.9% sodium chloride.

Intramuscular injection

Reconstitute 500 mg in 2 ml of water for injection

Reconstitute 1 g in 2.5 ml of water for injection

Intrapleural

Reconstitute 250 mg in 5 to 10 ml of water for injection.

Intra-articular

Reconstitute 250 mg to 500 mg in up to 5 ml of water for injection or in 0.5% lignocaine hydrochloride solution.

7 MEDICINE SCHEDULE

Prescription medicine.

8 SPONSOR

CARSL Consulting

P O Box 766

Hastings 4156, New Zealand

Phone: 0275086002

www.carsl.co.nz

carsl@xtra.co.nz

Distributed by

Eugia Pharma (Australia) Pty Ltd
25 Milton Parade
MALVERN VIC 3144
www.eugiapharma.com.au
eugia.aus@eugiapharma.com

9 DATE OF FIRST APPROVAL

19 December 2025

10 DATE OF REVISION OF THE TEXT

10 September 2025

SUMMARY TABLE OF CHANGES

Section Changed	Summary of new information
N/A	New product registration

